The global PD-L1 Biomarker Testing market size was valued at US$ 1438.5 million in 2023. With growing demand in downstream market, the PD-L1 Biomarker Testing is forecast to a readjusted size of US$ 15280 million by 2030 with a CAGR of 40.1% during review period.
The research report highlights the growth potential of the global PD-L1 Biomarker Testing market. PD-L1 Biomarker Testing are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of PD-L1 Biomarker Testing. Market players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the PD-L1 Biomarker Testing market.
PD-L1 Biomarker Testing measures the amount of PDL1 on cancer cells. PDL1 is a protein that helps keep immune cells from attacking nonharmful cells in the body. Normally, the immune system fights foreign substances like viruses and bacteria, and not your own healthy cells. Some cancer cells have high amounts of PDL1. This allows the cancer cells to "trick" the immune system, and avoid being attacked as foreign, harmful substances.
Current PD-L1 testing is based on immunohistochemistry (IHC) methods. Immunohistochemistry (IHC) is the process whereby antibodies are used to detect proteins (antigens) in cells within a tissue section (for instance liver, pancreas or the heart).
PD-L1 is a ligand that binds to PD-1 (programmed cell death-1), expressed on activated T cells, to evade anti-tumor responses. PD-L1 plays a role in inhibiting T cell activation and proliferation and has emerged as an important target in cancer treatment. PD-L1 protein detection by immunohistochemistry (IHC) testing is widely used as a predictive biomarker assay for anti鈥揚D-1/PD-L1 therapies.
PDL1 testing is used to find out if you have a cancer that may benefit from immunotherapy.
The classification of PD-L1 Biomarker Testing includes PD-L1 (22C3), PD-L1 (28-8), PD-L1 (SP142), PD-L1 (SP263) and Other, and the revenue proportion of PD-L1 (22C3) in 2019 is about 21.68%.
PD-L1 Biomarker Testing is widely used in Hospital and Diagnostic Laboratories. The most proportion of PD-L1 Biomarker Testing is Hospital, and the proportion in 2019 is about 52.7%.
North Americas is the largest consumption place, with a consumption market share nearly 55.63% in 2019. Following North Americas, Europe is the second largest consumption place with the consumption market share of 26.7%.
Key Features:
The report on PD-L1 Biomarker Testing market reflects various aspects and provide valuable insights into the industry.
Market Size and Growth: The research report provide an overview of the current size and growth of the PD-L1 Biomarker Testing market. It may include historical data, market segmentation by Type (e.g., PD-L1 (22C3), PD-L1(28-8)), and regional breakdowns.
Market Drivers and Challenges: The report can identify and analyse the factors driving the growth of the PD-L1 Biomarker Testing market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs.
Competitive Landscape: The research report provides analysis of the competitive landscape within the PD-L1 Biomarker Testing market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.
Technological Developments: The research report can delve into the latest technological developments in the PD-L1 Biomarker Testing industry. This include advancements in PD-L1 Biomarker Testing technology, PD-L1 Biomarker Testing new entrants, PD-L1 Biomarker Testing new investment, and other innovations that are shaping the future of PD-L1 Biomarker Testing.
Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the PD-L1 Biomarker Testing market. It includes factors influencing customer ' purchasing decisions, preferences for PD-L1 Biomarker Testing product.
Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the PD-L1 Biomarker Testing market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting PD-L1 Biomarker Testing market. The report also evaluates the effectiveness of these policies in driving market growth.
Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the PD-L1 Biomarker Testing market.
Market Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the PD-L1 Biomarker Testing industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.
Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the PD-L1 Biomarker Testing market.
Market Segmentation:
PD-L1 Biomarker Testing market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Segmentation by type
PD-L1 (22C3)
PD-L1(28-8)
PD-L1 (SP142)
PD-L1 (SP263)
Other
Segmentation by application
Hospital
Diagnostic Center
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Agilent Technologies
Roche
Merck
Bristol-Myers Squibb
AstraZeneca
Ono Pharmaceutical
Regeneron
Innovent
Hengrui Medicine
Junshi Biosciences
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global PD-L1 Biomarker Testing Market Size 2019-2030
2.1.2 PD-L1 Biomarker Testing Market Size CAGR by Region 2019 VS 2023 VS 2030
2.2 PD-L1 Biomarker Testing Segment by Type
2.2.1 PD-L1 (22C3)
2.2.2 PD-L1(28-8)
2.2.3 PD-L1 (SP142)
2.2.4 PD-L1 (SP263)
2.2.5 Other
2.3 PD-L1 Biomarker Testing Market Size by Type
2.3.1 PD-L1 Biomarker Testing Market Size CAGR by Type (2019 VS 2023 VS 2030)
2.3.2 Global PD-L1 Biomarker Testing Market Size Market Share by Type (2019-2024)
2.4 PD-L1 Biomarker Testing Segment by Application
2.4.1 Hospital
2.4.2 Diagnostic Center
2.4.3 Others
2.5 PD-L1 Biomarker Testing Market Size by Application
2.5.1 PD-L1 Biomarker Testing Market Size CAGR by Application (2019 VS 2023 VS 2030)
2.5.2 Global PD-L1 Biomarker Testing Market Size Market Share by Application (2019-2024)
3 PD-L1 Biomarker Testing Market Size by Player
3.1 PD-L1 Biomarker Testing Market Size Market Share by Players
3.1.1 Global PD-L1 Biomarker Testing Revenue by Players (2019-2024)
3.1.2 Global PD-L1 Biomarker Testing Revenue Market Share by Players (2019-2024)
3.2 Global PD-L1 Biomarker Testing Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 PD-L1 Biomarker Testing by Regions
4.1 PD-L1 Biomarker Testing Market Size by Regions (2019-2024)
4.2 Americas PD-L1 Biomarker Testing Market Size Growth (2019-2024)
4.3 APAC PD-L1 Biomarker Testing Market Size Growth (2019-2024)
4.4 Europe PD-L1 Biomarker Testing Market Size Growth (2019-2024)
4.5 Middle East & Africa PD-L1 Biomarker Testing Market Size Growth (2019-2024)
5 Americas
5.1 Americas PD-L1 Biomarker Testing Market Size by Country (2019-2024)
5.2 Americas PD-L1 Biomarker Testing Market Size by Type (2019-2024)
5.3 Americas PD-L1 Biomarker Testing Market Size by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC PD-L1 Biomarker Testing Market Size by Region (2019-2024)
6.2 APAC PD-L1 Biomarker Testing Market Size by Type (2019-2024)
6.3 APAC PD-L1 Biomarker Testing Market Size by Application (2019-2024)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe PD-L1 Biomarker Testing by Country (2019-2024)
7.2 Europe PD-L1 Biomarker Testing Market Size by Type (2019-2024)
7.3 Europe PD-L1 Biomarker Testing Market Size by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa PD-L1 Biomarker Testing by Region (2019-2024)
8.2 Middle East & Africa PD-L1 Biomarker Testing Market Size by Type (2019-2024)
8.3 Middle East & Africa PD-L1 Biomarker Testing Market Size by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Global PD-L1 Biomarker Testing Market Forecast
10.1 Global PD-L1 Biomarker Testing Forecast by Regions (2025-2030)
10.1.1 Global PD-L1 Biomarker Testing Forecast by Regions (2025-2030)
10.1.2 Americas PD-L1 Biomarker Testing Forecast
10.1.3 APAC PD-L1 Biomarker Testing Forecast
10.1.4 Europe PD-L1 Biomarker Testing Forecast
10.1.5 Middle East & Africa PD-L1 Biomarker Testing Forecast
10.2 Americas PD-L1 Biomarker Testing Forecast by Country (2025-2030)
10.2.1 United States PD-L1 Biomarker Testing Market Forecast
10.2.2 Canada PD-L1 Biomarker Testing Market Forecast
10.2.3 Mexico PD-L1 Biomarker Testing Market Forecast
10.2.4 Brazil PD-L1 Biomarker Testing Market Forecast
10.3 APAC PD-L1 Biomarker Testing Forecast by Region (2025-2030)
10.3.1 China PD-L1 Biomarker Testing Market Forecast
10.3.2 Japan PD-L1 Biomarker Testing Market Forecast
10.3.3 Korea PD-L1 Biomarker Testing Market Forecast
10.3.4 Southeast Asia PD-L1 Biomarker Testing Market Forecast
10.3.5 India PD-L1 Biomarker Testing Market Forecast
10.3.6 Australia PD-L1 Biomarker Testing Market Forecast
10.4 Europe PD-L1 Biomarker Testing Forecast by Country (2025-2030)
10.4.1 Germany PD-L1 Biomarker Testing Market Forecast
10.4.2 France PD-L1 Biomarker Testing Market Forecast
10.4.3 UK PD-L1 Biomarker Testing Market Forecast
10.4.4 Italy PD-L1 Biomarker Testing Market Forecast
10.4.5 Russia PD-L1 Biomarker Testing Market Forecast
10.5 Middle East & Africa PD-L1 Biomarker Testing Forecast by Region (2025-2030)
10.5.1 Egypt PD-L1 Biomarker Testing Market Forecast
10.5.2 South Africa PD-L1 Biomarker Testing Market Forecast
10.5.3 Israel PD-L1 Biomarker Testing Market Forecast
10.5.4 Turkey PD-L1 Biomarker Testing Market Forecast
10.5.5 GCC Countries PD-L1 Biomarker Testing Market Forecast
10.6 Global PD-L1 Biomarker Testing Forecast by Type (2025-2030)
10.7 Global PD-L1 Biomarker Testing Forecast by Application (2025-2030)
11 Key Players Analysis
11.1 Agilent Technologies
11.1.1 Agilent Technologies Company Information
11.1.2 Agilent Technologies PD-L1 Biomarker Testing Product Offered
11.1.3 Agilent Technologies PD-L1 Biomarker Testing Revenue, Gross Margin and Market Share (2019-2024)
11.1.4 Agilent Technologies Main Business Overview
11.1.5 Agilent Technologies Latest Developments
11.2 Roche
11.2.1 Roche Company Information
11.2.2 Roche PD-L1 Biomarker Testing Product Offered
11.2.3 Roche PD-L1 Biomarker Testing Revenue, Gross Margin and Market Share (2019-2024)
11.2.4 Roche Main Business Overview
11.2.5 Roche Latest Developments
11.3 Merck
11.3.1 Merck Company Information
11.3.2 Merck PD-L1 Biomarker Testing Product Offered
11.3.3 Merck PD-L1 Biomarker Testing Revenue, Gross Margin and Market Share (2019-2024)
11.3.4 Merck Main Business Overview
11.3.5 Merck Latest Developments
11.4 Bristol-Myers Squibb
11.4.1 Bristol-Myers Squibb Company Information
11.4.2 Bristol-Myers Squibb PD-L1 Biomarker Testing Product Offered
11.4.3 Bristol-Myers Squibb PD-L1 Biomarker Testing Revenue, Gross Margin and Market Share (2019-2024)
11.4.4 Bristol-Myers Squibb Main Business Overview
11.4.5 Bristol-Myers Squibb Latest Developments
11.5 AstraZeneca
11.5.1 AstraZeneca Company Information
11.5.2 AstraZeneca PD-L1 Biomarker Testing Product Offered
11.5.3 AstraZeneca PD-L1 Biomarker Testing Revenue, Gross Margin and Market Share (2019-2024)
11.5.4 AstraZeneca Main Business Overview
11.5.5 AstraZeneca Latest Developments
11.6 Ono Pharmaceutical
11.6.1 Ono Pharmaceutical Company Information
11.6.2 Ono Pharmaceutical PD-L1 Biomarker Testing Product Offered
11.6.3 Ono Pharmaceutical PD-L1 Biomarker Testing Revenue, Gross Margin and Market Share (2019-2024)
11.6.4 Ono Pharmaceutical Main Business Overview
11.6.5 Ono Pharmaceutical Latest Developments
11.7 Regeneron
11.7.1 Regeneron Company Information
11.7.2 Regeneron PD-L1 Biomarker Testing Product Offered
11.7.3 Regeneron PD-L1 Biomarker Testing Revenue, Gross Margin and Market Share (2019-2024)
11.7.4 Regeneron Main Business Overview
11.7.5 Regeneron Latest Developments
11.8 Innovent
11.8.1 Innovent Company Information
11.8.2 Innovent PD-L1 Biomarker Testing Product Offered
11.8.3 Innovent PD-L1 Biomarker Testing Revenue, Gross Margin and Market Share (2019-2024)
11.8.4 Innovent Main Business Overview
11.8.5 Innovent Latest Developments
11.9 Hengrui Medicine
11.9.1 Hengrui Medicine Company Information
11.9.2 Hengrui Medicine PD-L1 Biomarker Testing Product Offered
11.9.3 Hengrui Medicine PD-L1 Biomarker Testing Revenue, Gross Margin and Market Share (2019-2024)
11.9.4 Hengrui Medicine Main Business Overview
11.9.5 Hengrui Medicine Latest Developments
11.10 Junshi Biosciences
11.10.1 Junshi Biosciences Company Information
11.10.2 Junshi Biosciences PD-L1 Biomarker Testing Product Offered
11.10.3 Junshi Biosciences PD-L1 Biomarker Testing Revenue, Gross Margin and Market Share (2019-2024)
11.10.4 Junshi Biosciences Main Business Overview
11.10.5 Junshi Biosciences Latest Developments
12 Research Findings and Conclusion
听
听
*If Applicable.
